** Shares of diagnostic company Quanterix rise 1.2% to $27.31
** Co announces that the U.S. FDA has granted its blood test 'breakthrough device' designation
** 'Breakthrough device' designation helps patients gain access to medical devices in treatments for which no approved or cleared alternatives exist
** The blood test called Simoa helps in detecting a protein, p-Tau 217, to help diagnose Alzheimer’s Disease
** The test is not intended as a stand-alone test and its results will be interpreted along with other diagnostic tools - QTRX
** Including session moves, stock has doubled in the last 12 months
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))
Comments